Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Q4 2019 Eli Lilly and Co Earnings Call Transcript

Jan 30, 2020 / 02:00PM GMT
Release Date Price: R$19.41
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q4 2019 Earnings Call. (Operator Instructions) As a reminder, today's call is being recorded.

I'd now like to turn the conference over to your host, Kevin Hern. Please go ahead.

Kevin Hern
Eli Lilly and Company - VP of IR

Good morning. Thank you for joining us for Eli Lilly and Company's Q4 2019 Earnings Call.

I'm Kevin Hern, Vice President of Investor Relations. Joining on today's call are Dave Ricks, Lilly's Chairman and CEO; Josh Smiley, Chief Financial Officer; Dr. Dan Skovronsky, Chief Scientific Officer; Anne White, President of Lilly Oncology; Patrik Jonsson, President of Lilly Bio-Medicines; and Mike Mason, President of Lilly Diabetes. We're also joined by Kim Macko and Mike Czapar of the Investor Relations team.

During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3 and those

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot